Assessment of antiangiogenic and antivascular therapeutics using MRI: recommendations for appropriate methodology for clinical trials
- 1 December 2003
- journal article
- review article
- Published by Oxford University Press (OUP) in The British Journal of Radiology
- Vol. 76 (suppl_1) , S87-S91
- https://doi.org/10.1259/bjr/15917261
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I StudiesJournal of Clinical Oncology, 2003
- Combretastatin A4 Phosphate Has Tumor Antivascular Activity in Rat and Man as Demonstrated by Dynamic Magnetic Resonance ImagingJournal of Clinical Oncology, 2003
- Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic AntibodiesJNCI Journal of the National Cancer Institute, 2002
- Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance ImagingJournal of Clinical Oncology, 2002
- Dynamic contrast‐enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti‐angiogenic therapy in a xenograft model of glioblastoma multiformeJournal of Magnetic Resonance Imaging, 2002
- Estimating kinetic parameters from dynamic contrast-enhanced t1-weighted MRI of a diffusable tracer: Standardized quantities and symbolsJournal of Magnetic Resonance Imaging, 1999
- Key factors in the acquisition of contrast kinetic data for oncologyJournal of Magnetic Resonance Imaging, 1999
- Modeling tracer kinetics in dynamic Gd‐DTPA MR imagingJournal of Magnetic Resonance Imaging, 1997